Molecular profiling - An essential technology enabling personalized medicine in breast cancer

Jiangang Liu, Shuyu Li, A. Dunker, Vladimir N. Uversky

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.

Original languageEnglish (US)
Pages (from-to)541-554
Number of pages14
JournalCurrent Drug Targets
Volume13
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Precision Medicine
Medicine
Tumors
Breast Neoplasms
Technology
Neoplasms
Recurrence
Screening
Therapeutics
Survival Rate
Mortality

Keywords

  • Biomarker
  • Breast cancer
  • Gene signature
  • Intrinsically disordered protein
  • Molecular profiling
  • Personalized medicine
  • Prognostic factor
  • Protein-protein interaction

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Molecular profiling - An essential technology enabling personalized medicine in breast cancer. / Liu, Jiangang; Li, Shuyu; Dunker, A.; Uversky, Vladimir N.

In: Current Drug Targets, Vol. 13, No. 4, 04.2012, p. 541-554.

Research output: Contribution to journalArticle

Liu, Jiangang ; Li, Shuyu ; Dunker, A. ; Uversky, Vladimir N. / Molecular profiling - An essential technology enabling personalized medicine in breast cancer. In: Current Drug Targets. 2012 ; Vol. 13, No. 4. pp. 541-554.
@article{2a9b762abdf44a8d9a14478650d67ba9,
title = "Molecular profiling - An essential technology enabling personalized medicine in breast cancer",
abstract = "Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.",
keywords = "Biomarker, Breast cancer, Gene signature, Intrinsically disordered protein, Molecular profiling, Personalized medicine, Prognostic factor, Protein-protein interaction",
author = "Jiangang Liu and Shuyu Li and A. Dunker and Uversky, {Vladimir N.}",
year = "2012",
month = "4",
doi = "10.2174/138945012799499767",
language = "English (US)",
volume = "13",
pages = "541--554",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Molecular profiling - An essential technology enabling personalized medicine in breast cancer

AU - Liu, Jiangang

AU - Li, Shuyu

AU - Dunker, A.

AU - Uversky, Vladimir N.

PY - 2012/4

Y1 - 2012/4

N2 - Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.

AB - Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.

KW - Biomarker

KW - Breast cancer

KW - Gene signature

KW - Intrinsically disordered protein

KW - Molecular profiling

KW - Personalized medicine

KW - Prognostic factor

KW - Protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=84863292154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863292154&partnerID=8YFLogxK

U2 - 10.2174/138945012799499767

DO - 10.2174/138945012799499767

M3 - Article

C2 - 22250651

AN - SCOPUS:84863292154

VL - 13

SP - 541

EP - 554

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 4

ER -